FOUNDATION FOR THE ADVANCEMENT OF CARDIOLOGY CARDIOPROGRESS
  
  KNOWLEDGE, OBSERVATION, ACTION

RUS      ENG    
        

Monday, 23 July 2018

HomeAboutInternational Forum of Cardiology and Internal MedicineRussian Cardio AgendaWorld Cardio AgendaEducational projectsGuidelineslinical trialsJournalsNewsArchive

News
  • Studies Find No Easy Predictors of Stroke Prevention in TAVR ...
  • Statins in Peripheral Artery Disease: What Are We Waiting For? ...
  • Beta-Blockers May Raise Mortality in People With Diabetes ...
  • Dementia Risk Higher in Congenital Heart Disease Survivors ...
  • New health trackers warn of heart-attack risk, discreetly ...
     

    Partnership
    The Department of Health in Moscow
    The State Committee on Health
    Silicea-Poligraf, publishing house

    Follow us:
    @moscowcardio               Facebook

     <<  return

     

     

                It is unclear whether modifying cholesterol, blood pressure, or both affect erectile dysfunction. Also, there are concerns that erectile dysfunction is worsened by common medications used to treat these risk factors. In this study, we evaluated the effect of: (1) cholesterol-lowering with a statin; (2) pharmacologic blood pressure reduction; and (3) their combination, on erectile function.

                A priori, this was a secondary analysis of the Heart Outcomes Prevention Evaluation-3 (HOPE-3) randomized controlled trial. Men were 55 years of age or older with at least 1 cardiovascular risk factor. Erectile function was measured using the erectile function domain of the International Index of Erectile Function (IIEF-EF) score. Men with incomplete scores, or who did not engage in sexual activity, were excluded. Using a 2 × 2 factorial design, participants were randomized to rosuvastatin (10 mg/d) or placebo, and to candesartan with hydrochlorothiazide (HCTZ; 16 mg/12.5 mg/d; Cand+HCTZ) or placebo. Primary outcome was change in IIEF-EF from baseline to end of study follow-up.

                Two thousand one hundred fifty-three men were included; mean age was 61.5 years, and mean follow-up was 5.8 years. Mean IIEF-EF score at baseline was 23.0 (SD 5.6). Least square mean change in the IIEF-EF score did not differ with rosuvastatin compared with placebo (-1.4; standard error [SE], 0.3 vs -1.5; SE, 0.3; P = 0.74), Cand+HCTZ compared with placebo (-1.6; SE, 0.3 vs -1.3; SE, 0.3; P = 0.10), or combination therapy compared with double placebo (P = 0.35).

                Cholesterol-lowering using a statin, and blood pressure-lowering using Cand+HCTZ, either alone or in combination, do not improve or adversely affect erectile function.

    https://www.medscape.com/viewarticle/892745





    Feedback

    Contact us: by  

    Editor-in-chief:  

    @Mail.ru
    Main | About | International Forum of Cardiology and Internal Medicine | Russian Cardio Agenda | World Cardio Agenda | Educational projects | Guidelines | linical trials | Journals | News | Archive
    2012-2018. Foundation for Promotion of Cardiology